Translational Proteomics for Obesity Clinical Trials
Generating mechanistic and biomarker insights from large-scale proteomics in phase 2/3 obesity programs.
At Lilly, I work at the intersection of clinical omics and drug development, applying large-scale proteomics (primarily Olink and SomaScan platforms) to phase 2 and phase 3 clinical trials for obesity and cardiometabolic disease. The goal is to translate protein abundance changes measured in trial participants into mechanistic hypotheses about drug biology and actionable biomarker strategies that inform clinical decisions.
This work requires bridging statistical genetics, proteomics methodology, and clinical endpoint analysis: interpreting proteomic trajectories in the context of pQTL and genetic association data, applying survival analysis and mixed models to longitudinal omics data, and integrating electronic health record data to characterize patient subgroups. I also build the analytical infrastructure (pipelines, data models, dashboards) that supports the broader clinical omics team.
Related: UK Biobank Pharma Proteomics Project — the foundational proteomics resource that guide some of the analytical work described above.